Sandostatin LAR in acromegalic patients: Long term treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 1, 1997, Pages 23-28

  Fløgstad, Anette Kvistborg ^a,c   Halse, Johan ^a   Bakke, Søren ^a   Lancranjan, Ioana ^b   Marbach, P ^b   Bruns, Ch ^b   Jervell, Jak ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Sandoz Pharma Ltd   (Switzerland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ACROMEGALY; ADULT; ALOPECIA; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GALLSTONE; GASTROINTESTINAL TOXICITY; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HORMONE INHIBITION; HUMAN; HYPOPHYSIS TUMOR; LONG TERM CARE; MALE; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0031023098     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.1.23     Document Type: Article

References (24)

1. Vance ML, Harris AG. 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the internal multicenter acromegaly study group. Arch Intern Med. 151:1573-1578.
2. Ezzat S, Snyder PJ, Young WF, et al. 1992 Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med. 117:711-718.
3. Arosio M, Macchelli S, Rossi CM, et al. 1995 Effects of the treatment with octreotide in acromegalic patients-a multicenter Italian study. Eur J Endocrinol. 133:430-439.
4. Fløgstad A.K., Halse J, Haldorsen T, Lancranjan I, Jervell J. 1995 Sandostatin® LAR® in acromegalic patients: a dose-response study. J Clin Endocrinol Metab. 80:3601-3607.
5. Lamberts SWJ, Uitterlinden P, Del Pozo E. 1987 SMS 201-995 induces a continuous decline in circulating growth hormone and somatostatin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 65:703-710.
6. Christensen C, Weeke J, Ørskov H, et al. 1987 Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf). 27:297-306.
7. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. 1988 Treatment of acromegaly with the long-acting somatostatin analog 201-995. J Clin Endocrinol Metab. 66:16-23.
8. Barkan AL, Lloyd RV, Chandler WF, et al. 1988 Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab. 67:1040-1048.
9. Tauber JP, Babin Th, Tauber MT, et al. 1989 Long term effect of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 68:917-924.
10. James RA, Chatterjee S, White MC, Hall K, Møller N, Kendall-Taylor P. 1989 Continuous infusion of octreotide in acromegaly. Lancet. 2:1083-1087.
11. Sassolas G, Harris AG, James-Deidier A, The French SMS 201-995 Acromegaly Study Group. 1990 Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
12. Stewart PM, Kane FK, Stewart SE, Lancranjan I, Sheppard MC. 1995 Depot long-acting somatostatin analog (Sandostatin® LAR®) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 80:3267-3272.
13. Fløgstad AK, Halse J, Grass P, et al. 1994 A comparison of octreotide, bromocriptine or a combination of both drugs in acromegaly. J Clin Endocrinol Metab. 79:461-465.
14. Flyvberg A, Jørgensen KD, Marshall SM, Ørskov H. 1991 Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and ovarian growth in the hypophysectomized rats. Am J Physiol. 260:568-574.
15. Ezzat S, Ren SG, Braunstein GD, Melmed S. 1992 Octreotide stimulates insulin-like growth factor-binding protein-1:a potential pituitary independent mechanism for action. J Clin Endocrinol Metab. 75:1459-1463.
16. Lamberts SWJ, Verleun T, Zuidervijk JM, Oosterom R. 1987 The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion. Acta Endocrinol (Copenh). 115:196.
17. Bauer W, Briner U, Doepfner R, et al. 1982 A very potent and selective octrapeptide analog of somatostatin with prolonged action. Life Sci. 31:1133-1140.
18. Davidson MB. 1987 Effects of GH on carbohydrate and lipid metabolism. Endocr Rev. 8:115-131.
19. Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M. 1995 Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res. 27:226-230.
20. Halse J, Harris AG, Kvistborg A, et al. 1990 A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab. 79:461-465.
21. Ho KK, Jenkins AB, Furler SM, Borkman M, Chrisholm DJ. 1992 Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf). 36:271-279.
22. Koop BL, Harris AG, Ezzat S. 1994 Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol. 130:581-586.
23. Pløckinger U, Dienemann D, Quabbe HJ. 1990 Gastrointestinal side-effects of octreotide during long term treatment of acromegaly. J Clin Endocrinol Metab. 71:1658-1662.
24. Nakauchi Y, Kumon Y, Yamasaki H, Tahara K, Kurisaka M, Hashimoto K. 1995 Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. Endocr J. 42:385-389.